<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>19085641</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Elizalde-Montagut, J</dc:author>
<dc:author>Piñero, A M</dc:author>
<dc:author>Sempere, J</dc:author>
<dc:author>Nadal, J</dc:author>
<dc:description xml:lang="en">PURPOSE To describe our experience in the diagnosis of Familial Exudative Vitreoretinopathy (FEVR) at its different clinical stages. We also report our outcomes in early treatment of this inherited disorder. METHODS Retrospective interventional and descriptive case series of 11 patients (17 eyes) affected by FEVR evaluated and treated in our hospital. RESULTS In our series, 33.3% of patients were classified as stage I, while 16.7% and 50% were classified as stage II and III, respectively. Visual acuity (VA) remained stable after treatment in stages I and II (mean VA was 0.8 and 0.4, respectively) but decreased in stage III. CONCLUSIONS Early treatment of FERV may improve the visual prognosis and avoid complications such as subfoveal chronic exudation and vitreoretinal peripheral interphase contraction and fibrosis.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2008 Dec </dc:date>
<dc:title xml:lang="es">Vitreorretinopatía exudativa familiar: nuestra experiencia.</dc:title>
<dc:title xml:lang="en">[Familial exudative vitreoretinopathy: our experience].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
